Medical Research On Investment Value Of Listed Companies

From a worldwide view, China’s capital market at an early stage of development. Mainly sold to individual investors in the stock market, which investors often lack scientific and rational investment analysis system, which in turn leads to irrational emotions occur in Chinese stock market, it is hard to get income from the stock market. This paper aims to present macroeconomic situation, economic performance is still good and still has good expectations for future development of the pharmaceutical industry for investors under the current capital market situation and make investment recommendations. A case study of YUNNAN BAIYAO, providing investors with a scientific investment analysis system, for reference by investors in the investment decision-making process to be, after the last hope to see investors make rational investment enabled the stock market to improve further.This article will use the fundamental analysis of the qualitative and financial analysis of the investment value of quantitative analysis of YUNNAN BAIYAO analysis report. Paper first from medicine industry by face of external environment starts with, as healthcare, population aging, external effect company valuation of factors cut, then gradually in-depth to YUNNAN BAIYAO company internal, from its competitiveness, financial status, future development potential and faced of challenge, many, from qualitative angle evaluation its investment value, last with relative valuation model in the of amendment earnings, and amendment city net rate valuation model and absolute valuation model in the of cash flow folding now method quantitative YUNNAN BAIYAO of investment value. As a comprehensive qualitative and quantitative valuation point of research on investment value of YUNNAN BAIYAO, eventually came to possess the necessary research on investment value of YUNNAN BAIYAO conclusion.Evaluation of existing pharmaceutical enterprises in the investment value of the article, which is more from this single view evaluation of the financial statements the value of their investments, this article from the macroeconomic situation, industry prospects, company competitiveness and financial statements comprehensive evaluating the investment value of YUNNAN BAIYAO. First part of this article is the introduction, in turn, introduces the background, significance, and research ideas and method of studies, research and innovation. Second part of YUNNAN BAIYAO status quo and factors affecting the valuation of the company. The third part is the overall analysis of YUNNAN BAIYAO medicine industry. Part IV is a financial statement analysis of YUNNAN BAIYAO. Part v of the YUNNAN BAIYAO is SWOT analysis and analysis of the economic value added. Part VI is the valuation analysis of YUNNAN BAIYAO. Part VII is YUNNAN BAIYAO investment risk analysis and investment advice.After more than seven parts of analysis and research to arrive at a final conclusion:1, increased with aging, health-care investment continued to increase, YUNNAN BAIYAO as leader of the pharmaceutical industry in the field of medicine, will continue to benefit from the above two trends in the future.2, industrial policy of YUNNAN BAIYAO also benefit, such as tendering policy. YUNNAN BAIYAO in Yunnan Bai Yao series,37 and Yunnan ethnic medicines series-oriented, product-specific attribute strong in a tendering policy products is expected to further increase.3, the relative valuation model, the intrinsic value of YUNNAN BAIYAO in [79.38,81.51] in the area, absolute valuation model, the intrinsic value of YUNNAN BAIYAO to 88.12, as of March 6,2016, YUNNAN BAIYAO’s closing price of 57.60 Yuan, its share price far below its intrinsic value, display of YUNNAN BAIYAO was undervalued by the market, shares with a large margin of safety. In convulsive moment in the stock market, investors should be concerned about drug companies that has defensive properties and recommended that investors hold subject of Yunnan white drug-company shares.